FDA Bans Import of Drugs from Dr. Reddy's Mexico Site - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Bans Import of Drugs from Dr. Reddy's Mexico Site


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA banned the importation of products manufactured at the Mexican unit of Dr. Reddy’s Laboratories, according to Reuters. The import ban is a result of the company’s failure to correct the violations listed in a June 3, 2011, Warning Letter to the agency’s satisfaction.

FDA inspected the Cuernavaca, Mexico, facility, which manufactures active pharmaceutical ingredients (APIs), on Nov. 8–11, 2010, and found several cGMP violations. In the letter, the agency wrote that Dr. Reddy’s had not validated analytical methods for testing APIs, and that the company’s quality unit was not ensuring that APIs manufactured at the site were in compliance with cGMP and met specifications for quality and purity. In addition, FDA found the firm’s cleaning validation to be incomplete for nondedicated manufacturing equipment. Finally, the agency wrote that the site’s out-of-specification investigations did not include an analysis of all available data.

Dr. Reddy’s responded to FDA’s initial observations by implementing several corrective actions. In the Warning Letter, FDA called the company’s response insufficient and asked for additional data and corrective actions.

“Until all corrections have been completed and FDA has confirmed corrections of the deviations and your firm’s compliance with cGMP, FDA may withhold approval of any new applications or supplements listing your firm as an API manufacturer,” said the letter. “In addition, failure to correct these deviations may result in FDA refusing admission of articles manufactured at Industrias Quimicas Falcon de Mexico, S.A. de C.V. (also known as Dr. Reddy’s Mexico) into the United States.” Dr. Reddy’s acknowledged receipt of the Warning Letter on June 14, 2011.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here